Tramadol Pretreatment for Anti-NMDA Receptor Encephalitis Plasma Exchange
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anti-NMDA receptor encephalitis, such as immunotherapy with steroids and therapeutic plasma exchange, only improve symptoms in about half of patients within 4 weeks and have a high relapse rate, necessitating second-line therapies and prolonged recovery times.
Innovation Solution
Administering a therapeutically effective amount of tramadol before or during therapeutic plasma exchange to enhance the efficacy of plasma exchange and facilitate the removal of NMDA receptor antibodies, thereby improving symptom relief and reducing relapse rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy with steroids and therapeutic plasma exchange is used to treat anti-NMDA receptor encephalitis, then symptom improvement is achieved in about half of patients, but the treatment process takes months, requires hospitalization, and has a high relapse rate
Solution Approach 1:
The patent applies preliminary action by administering tramadol before therapeutic plasma exchange to block NMDA receptor activity in advance. This pre-treatment prevents antibody-receptor binding during the critical treatment window, making the subsequent plasma exchange more effective and accelerating symptom improvement without extending hospitalization duration.
2Reliability
If immunotherapy with steroids and therapeutic plasma exchange is used to treat anti-NMDA receptor encephalitis, then some symptom improvement is achieved, but relapse is common and second-line therapies are necessary
Solution Approach 1:
The patent uses tramadol as an intermediary substance that mediates between the pathogenic antibodies and NMDA receptors. Tramadol binds to NMDA receptors with high affinity, acting as a competitive antagonist that prevents antibody binding. This intermediary action provides robust protection against relapse by maintaining receptor blockade even when antibody levels fluctuate, reducing the need for second-line therapies.
3Ease of manufacture
If standard immunotherapy is used for anti-NMDA receptor encephalitis, then treatment can be initiated, but the therapy lacks sufficient effectiveness to prevent relapse and shorten recovery
Solution Approach 1:
The patent applies parameter changes by introducing tramadol, which has high affinity for NMDA receptors, to fundamentally alter the therapeutic parameter of receptor occupancy. This pharmacological intervention changes the binding dynamics at the receptor level, providing sustained blockade that prevents relapse and accelerates recovery while maintaining ease of administration through oral or intravenous routes.
Data Source
AI summary
The disclosure relates to compositions and methods for treating a subject suffering from anti-NMDA receptor encephalitis. The method comprises administering to a patient in need of treatment an effective amount of tramadol before and/or during administration of therapeutic plasma exchange.